SCHEMBL4524595

SCHEMBL4524595

O=c1cnc2c([N+](=O)[O-])cccc2[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.52
PKN1 Q16512 1/20 0.51
PKN2 Q16513 1/20 0.51
ALDH1A1 P00352 6/20 0.49
NOS1 P29475 4/20 0.49
PDE10A Q9Y233 1/20 0.47
MGAM O43451 1/20 0.46
GAA P10253 1/20 0.46
SI P14410 1/20 0.46
MGAM2 Q2M2H8 1/20 0.46
TDP1 Q9NUW8 4/20 0.43
KDM4E B2RXH2 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
NOS2 P35228 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
MAPT P10636 2/20 0.43
TSHR P16473 2/20 0.43
CYP2C19 P33261 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11843474 0.77 PKN1 (0.51) ADORA3PKN1PKN2ALDH1A1NOS1
SCHEMBL6332531 0.76 PKN1 (0.61) ADORA3PKN1PKN2ALDH1A1NOS1
SCHEMBL311327 0.76 PDE10A (0.50) ADORA3PKN1PKN2ALDH1A1NOS1
SCHEMBL6423203 0.76 PDE10A (0.50) ADORA3PKN1PKN2ALDH1A1NOS1
SCHEMBL4518440 0.75 ALDH1A1 (0.48) ADORA3ALDH1A1NOS1TDP1KDM4E
SCHEMBL1013588 0.75 PKN1 (0.60) ADORA3PKN1PKN2ALDH1A1NOS1
SCHEMBL13723653 0.74 ADORA3 (0.44) ADORA3ALDH1A1MGAMGAASI
SCHEMBL21530547 0.74 PARP1 (0.42) ALDH1A1MGAMGAASIMGAM2
SCHEMBL1041260 0.74 KDM4E (0.42) ALDH1A1PDE10AMGAMGAASI
SCHEMBL2359356 0.74 PSMB8 (0.45) ADORA3NOS1MGAMGAASI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137597-A1 Novel quinoxalinone derivatives MSD K.K. (JP) 2009-05-28 US disclosed
US-7388010-B2 Quinoxalinone derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-06-17 US disclosed
US-20060019959-A1 Novel quinoxalinone derivatives BANYU PHARMACEUTICAL CO., LTD. TSUKUBA RESEARCH INSTITUTE (JP) 2006-01-26 US disclosed
EP-1557418-A1 NOVEL QUINOXALINE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137597-A1 Novel quinoxalinone derivatives NDUFB1, NDUFB6, NDUFB7 ADORA3 2076/4885PKN1 1028/4885PKN2 868/4885
US-20060019959-A1 Novel quinoxalinone derivatives NDUFB1, NDUFB6, NDUFB11 ADORA3 2254/4885PKN1 936/4885PKN2 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.